This article is more than 5 years old. Information may no longer be current.

Othera receives patent for compounds targeting AMD, other ocular disorders

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EXTON, Pa. — The U.S. Patent and Trademark Office has issued Othera Pharmaceuticals the first patent covering a broad class of disubstituted hydroxylamine small molecules that target oxidative stress and inflammation involved in age-related macular degeneration and other ocular disorders.

U.S. Patent No. 7,442,711 covers several new chemical entities, including the company's lead product candidate, OT-551, a topically dosed small molecule that inhibits oxidative stress and disease-induced inflammation, according to a press release from Othera.

The company has completed enrollment for a phase 2 clinical trial called the OMEGA (OT-551 multi-center evaluation of geographic atrophy) study, in which OT-551 will be evaluated against placebo for treating geographic atrophy associated with AMD.

The 24-month, randomized, double-masked, dose-ranging, multicenter study has enrolled 137 patients in 20 retinal disease treatment centers across the United States.